ArticleMaterials today. Bio2025
Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Programmed death 1 antibody drug conjugates (PD 1 ADCs): Innovations in overcoming resistance and enhancing immune mediated antitumor activity.Translational oncology · 2026Review
- Polyphosphazene-Based Nanotherapeutics.Journal of functional biomaterials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy presents promising opportunities to target critical pathways in complex cancers like glioblastoma multiforme, though it necessitates the use of efficient delivery vectors. Polyphosphazenes (PPZs) are highly flexible materials that lead to biodegradable, high-performance materials in various applications, including gene delivery. In this work, we synthesized various PPZ derivatives, incorporating primary amines, secondary amines, hydrophilic, and hydrophobic groups, and evaluated their gene transfection capabilities in combination with an anionic polyphosphazene (6MHA-PPZ) that acts as a charge quencher and transfection enhancer. Combining 6MHA-PPZ with a hydrophobic polymer demonstrated the highest gene delivery efficiency and safety, significantly surpassing previous benchmarks. Using these optimized nanoparticles, we delivered a BMP4-expressing plasmid (pBMP4) in glioblastoma models. The pBMP4 nanoparticles, when combined with the chemotherapeutic agent temozolomide (Tz), resulted in significant reductions in tumor volume, improved survival rates in preclinical models, and normalized the expression of drug resistance markers, providing a synergistic antitumoral effect with Tz. This study highlights the potential of PPZ-based nanoparticles for gene delivery and suggests that the combination of pBMP4-NPs and Tz could offer a promising therapeutic strategy for treating glioblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.